drugset / Trial / NCT06781073
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
This is an multicenter, randomized，double-blind, controlled clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with TP regimen (Paclitaxel + Cisplatin) for treatment of IVB stage, recurrent or persistent cervical squamous cell carcinoma .
Timeline
- Start
- 2017-07-06
- Primary completion
- 2024-11-25
- Completion
- 2024-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |